title: Reply to Seddon, Schaaf, and Hesseling.
authors.forename: Kelly E
authors.initials: KE
authors.lastname: Dooley
authors.forename: Carole
authors.initials: C
authors.lastname: Mitnick
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Degroote
authors.forename: Ekwaro
authors.initials: E
authors.lastname: Obuku
authors.forename: Carol D
authors.initials: CD
authors.lastname: Hamilton
authors.forename: Mamodikoe
authors.initials: M
authors.lastname: Makhene
authors.forename: Sarita
authors.initials: S
authors.lastname: Shah
authors.forename: James C M
authors.initials: JC
authors.lastname: Brust
authors.forename: Nadza
authors.initials: N
authors.lastname: Durakovic
authors.forename: Eric
authors.initials: E
authors.lastname: Nuermberger
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents